Guillain–Barré Syndrome developing in a Patient with Graves’ Disease

Anirban Majumder, Sagar Basu

Abstract

Graves' disease (GD) and Guillain-Barre syndrome (GBS) are both autoimmune disorders and are triggered by interactions between genetic and environmental factors. GBS in patients who suffer from other autoimmune diseases is rarely reported, and the development of atypical GBS with cranial nerve involvement in a patient with GD has never been previously reported. Herein, we report a patient with GD and a rare form of pharyngo-cervico-brachial variety of GBS.

Keywords

Graves' disease, Guillain-Barre syndrome, pharyngo–cervico–brachial variety

Full Text:

Abstract HTML PDF

References

DeGroot LJ. Graves’ disease and the manifestations of thyrotoxicosis. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA)L MDText.com, Inc.;2000-2015 Jul 11.

Prabhakar BS, Bahn RS, Smith. TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev. 2003;24(6): 802–35. PMID: 14671007. https://doi.org/10.1210/er.2002-0020.

Olshansky A. Diagnosis and treatment of Guillain-Barre syndrome. Virtual Mentor. 2007;9(8):552-4. https://doi.org/10.1001/virtualmentor.2007.9.8.cprl1-0708.

Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994;51(7):671-5. PMID: 8018039.

Ziganshin RH, Ivanova OM, Lomakin YA, et al. The pathogenesis of the demyelinating form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics. 2016;15(7):2366-78. PMID: 27143409. PMCID: PMC4937510. https://doi.org/10.1074/mcp.M115.056036.

Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64(10):1519-23. PMID: 17923636. https://doi.org/10.1001/archneur.64.10.1519.

Ahn SW, Kim SH, Park BS, et al. Concurrence of multifocal motor neuropathy and Hashimoto’s thyroiditis. J Clin Neurol. 2011;7(3):168–72. PMID: 22087213 PMCID: PMC3212605. https://doi.org/10.3988/jcn.2011.7.3.168.

Martin S, Rieckmann P, Melchers I, et al. Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1. J Immunol. 1995;154(4):1951-5. PMID: 7836774.

Lee JH, An MA, Jeon JS, et al. Circulating intercellular adhesion molecule-1(ICAM-1) in sera of patients with Graves' disease and Hashimoto disease. Korean J Intern Med. 1995;10(1):10-5. PMID: 7626551. PMCID: PMC4532030.

Kharwar NK, Prasad KN, Singh K, Paliwal VK, Modi DR. Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain–Barré syndrome. Int J Neurosci. 2007;127(8):680-7. PMID: 27595159. https://doi.org/10.1080/00207454.2016.1231186.

Huang Y, Ying Z, Chen Z, et al. Thyroid hormone level is associated with the frequency and severity of Guillain-Barré syndrome. Int J Neurosci. 2017;127(10):893-9. PMID: 28042737. https://doi.org/10.1080/00207454.2016.1278541.

Cho YY, Joung JY, Jeong H, et al. Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis. Korean J Intern Med. 2013;28(6):724–7. PMID: 24307850. PMCID: PMC3847000. https://doi.org/10.3904/kjim.2013.28.6.724.